Étiquette : thérapeutiques psychédeliques

The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders, Giovanna Felipe Cavalcante e Costa et al., 2018

The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders Giovanna Felipe Cavalcante e Costa, Hisao Nishijo, Leonardo Ferreira Caixeta, and Tales Alexandre Aversi-Ferreira Hindawi - Evidence-Based Complementary and Alternative Medicine, Volume 2018, Article ID 7686913, 27 pages Doi : 10.1155/2018/7686913   Abstract For neurological disorders, pharmacological tests have shown promising results in the reduction of side effects when using plants with known therapeutic effects in the treatment of some types of dementia. Therefore, the goals of this study are to gather data about the major medicinal plants used in the nervous system as described in ethnopharmacological surveys from South [...]

Lire la suite

Translational evidence for ayahuasca as an antidepressant : what’s next ?

Translational evidence for ayahuasca as an antidepressant : what’s next ? Rafael Guimaraes dos SANTOS, José Carlos BOUSO British Journal of Psychiatry, 2019, 41, (4), 275-276. Doi : 10.1590/1516-4446-2019-4104   Depression is among the most important contributors to global disability and suicidal deaths. Available antidepressants are usually selective inhibitors of serotonin and norepinephrine uptake, which need weeks of daily intake before therapeutic effects appear, have limited efficacy for many patients, and induce significant adverse reactions after prolonged use. Therefore, recent research has focused on finding new antidepressant compounds that are fast-acting, more effective, and less toxic. The article recently published by da Silva et al. in the [...]

Lire la suite

Études psychédéliques, séminaire, Vincent Verroust, doctorant à l’EHESS, 2019-2020

Études psychédéliques Vincent Verroust, doctorant à l'EHESS ( CAK )Cet enseignant est référent pour cette UE https://enseignements-2019.ehess.fr/2019/ue/2998/   Mardi de 18 h à 19 h 30 (amphithéâtre Rouelle, Muséum national d'Histoire naturelle, 57 rue Cuvier 75005 Paris), les 26 novembre, 17 décembre 2019, 28 janvier, 25 février, 31 mars, 28 avril, 26 mai et 30 juin 2020 Plan pour trouver l'amphi : https://drive.google.com/file/d/1h-oVy6oTh7UTMh84X-o448VhCCmBMp-M/view?usp=sharing NB : merci d'arriver en avance pour éviter de trouver portes closes. Le terme psychedelic a été forgé en 1956 par le psychiatre britannique Humphry Osmond (1917 - 2004) pour qualifier les effets psychiques de la mescaline et du LSD, deux substances psychotropes sur lesquelles [...]

Lire la suite

Australia should be initiating a psychedelic research program : What are the barriers ?, Nigel Strauss et al., 2016

Australia should be initiating a psychedelic research program : What are the barriers ? Nigel Strauss, Stephen J Bright and Martin L Williams Australian & New Zealand Journal of Psychiatry, 2016, Vol. 50, (11), 1036–1037 DOI: 10.1177/0004867416670520   A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research in North America and Europe as investigators at Johns Hopkins School of Medicine, University of California, Los Angeles (UCLA), New York University and Imperial College London have embarked on studies that could be paradigm-changing for psychiatry (Nichols, 2016). These developments overturn a 30-year embargo on psychedelic research [...]

Lire la suite

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers, Rainer Kraehenmann et al., 2014

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010   Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]

Lire la suite

Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis, Alexander B. Belser et al., 2017

Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis and Stephen Ross Journal of Humanistic Psychology, 2017, 1 –35 Doi : 10.1177/0022167817706884 journals.sagepub.com/home/jhp   Abstract The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years (M = 50 years) with clinically elevated anxiety associated with a cancer [...]

Lire la suite

Soigner l’alcoolisme et la dépression avec des psychédéliques ? Entretien avec David Nutt, video, 2019

Soigner l'alcoolisme et la dépression avec des psychédéliques? Entretien avec David Nutt #RTSsanté , 11 avril 2019 https://www.youtube.com/watch?time_continue=55&v=D8QNY2bdNCk&feature=emb_logo Vidéo en complément du reportage « Le retour des psychédéliques » : https://youtu.be/503cSLA0Z38   Parmi les très nombreux articles cosignés par le Professeur David J. NUTT, du Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom, les références suivantes sont disponibles sur le site du GRECC :   Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity, Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. [...]

Lire la suite

Bibliographie : Psilocybes, psilocybine. Usages, ethnologie, psychiatrie, neurophysiologie, pharmacologie, spiritualité, thérapeutique…, Dr Christian Sueur, GRECC, octobre 2019

BIBLIOGRAPHIE : Psilocybes, psilocybine. Dr Christian SUEUR, GRECC, décembre 2019   Psilocybes, psilocybine : généralités ..............................1 Psilocybes : ethnologie ...................................................2 Psilocybine : clinique psychiatrique ..............................4 Psilocybine : pharmacologie ..........................................5 Psilocybine : toxicologie - "effets indésirables" .............7 Psilocybine : neurophysiologie ......................................9 Psilocybine : expériences mystiques .............................13 Psilocybine : thérapie psychédélique ............................15-19    

Lire la suite